GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axogen Inc (NAS:AXGN) » Definitions » Financial Strength

Axogen (Axogen) Financial Strength : 5 (As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is Axogen Financial Strength?

Axogen has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Axogen did not have earnings to cover the interest expense. Axogen's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.40. As of today, Axogen's Altman Z-Score is 0.56.


Competitive Comparison of Axogen's Financial Strength

For the Medical Devices subindustry, Axogen's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axogen's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Axogen's Financial Strength distribution charts can be found below:

* The bar in red indicates where Axogen's Financial Strength falls into.



Axogen Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Axogen's Interest Expense for the months ended in Dec. 2023 was $-1.8 Mil. Its Operating Income for the months ended in Dec. 2023 was $-3.2 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $67.7 Mil.

Axogen's Interest Coverage for the quarter that ended in Dec. 2023 is

Axogen did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Axogen's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.547 + 67.745) / 171.688
=0.40

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Axogen has a Z-score of 0.56, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of 0.56 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Axogen  (NAS:AXGN) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Axogen has the Financial Strength Rank of 5.


Axogen Financial Strength Related Terms

Thank you for viewing the detailed overview of Axogen's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Axogen (Axogen) Business Description

Traded in Other Exchanges
Address
13631 Progress Boulevard, Suite 400, Alachua, FL, USA, 32615
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Executives
Peter J Mariani officer: Chief Financial Officer C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Amy Mcbride Wendell director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Burke William P. Mr. director HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Guido J Neels director C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Marc A Began officer: EVP & General Counsel C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Joseph A. Tyndall director 13631 PROGRESS BLVD., SUITE 400, ALACHUA FL 32615
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Karen L. Zaderej director, officer: CEO AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Michael Patrick Donovan officer: VP Operations C/O AXOGEN, INC., 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL 32615
Maria D. Martinez officer: Chief Human Resources Officer C/O AXOGEN INC., 13631 PROGRESS BLVD, SUITE 400, ALACHUA FL 32615
Paul Thomas director ONE MILLENNIUM WAY, BRANCHBURG NJ 08876
Alan M Levine director C/O AXOGEN, INC., 13631 PROGRESS BLVD. - SUITE 400, ALACHUA FL 32615
Mark Stephen Gold director 13859 PROGRESS BLVD SUITE 100, ALACHUA FL 32615
Quentin S. Blackford director 7475 LUSK BLVD., SAN DIEGO CA 92121